CoChat
Cited by 168

The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.

Influencia de la infección SARS-CoV-2 sobre enfermedades neurodegenerativas y neuropsiquiátricas: ¿una pandemia demorada?

Open access
Serrano-Castro, P.J., Estivill-Torrús, G., Cabezudo-García, P., Reyes-Bueno, J.A., Ciano Petersen, N., Aguilar-Castillo, M.J., Suárez-Pérez, J., Jiménez-Hernández, M.D., Moya-Molina, M.Á., Oliver-Martos, B., Arrabal-Gómez, C., Rodríguez de Fonseca, F. · 2020 · Neurología

Abstract

La infección por el coronavirus SARS-CoV-2 originada en diciembre de 2019 en la región china de Wuhan ha adquirido proporciones pandémicas. A día de hoy ha ocasionado más de 1,7 millones de contagios y más de 100.000 muertes en todo el mundo. La investigación científica actual se centra en el mejor conocimiento de la infección aguda y de sus estrategias terapéuticas. Dada la magnitud de la epidemia, planteamos una revisión especulativa sobre las posibles consecuencias en patología neurológica a medio/largo plazo, con especial atención a enfermedades neurodegenerativas y neuropsiquiátricas con base neuroinflamatoria, teniendo en cuenta la evidencia directa de afectación neurológica a causa de la infección aguda. Revisamos de forma sistemática lo conocido sobre los mecanismos patogénicos de la infección por SARS-CoV-2, la repercusión de la tormenta de citoquinas sobre el sistema nervioso central y su persistencia en el tiempo y las consecuencias que la neuroinflamación puede tener sobre el sistema nervioso central. El SARS-CoV-2 es un virus neuroinvasivo capaz de provocar una tormenta de citoquinas que podría convertirse en persistente en población seleccionada. Aunque nuestra hipótesis tiene alto componente especulativo, la repercusión que esta situación puede tener en la puesta en marcha y progresión de enfermedades neurodegenerativas y neuropsiquiátricas con base neuroinflamatoria debe ser considerada como posible germen de una pandemia demorada que podría tener un gran impacto en salud pública a medio o largo plazo. Se hace necesario un estrecho seguimiento de la salud cognitiva y neuropsiquiátrica de los pacientes supervivientes a infección COVID-19. SARS-CoV-2 was first detected in December 2019 in the Chinese city of Wuhan and has since spread across the world. At present, the virus has infected over 1.7 million people and caused over 100 000 deaths worldwide. Research is currently focused on understanding the acute infection and developing effective treatment strategies. In view of the magnitude of the epidemic, we conducted a speculative review of possible medium- and long-term neurological consequences of SARS-CoV-2 infection, with particular emphasis on neurodegenerative and neuropsychiatric diseases of neuroinflammatory origin, based on the available evidence on neurological symptoms of acute SARS-CoV-2 infection. We systematically reviewed the available evidence about the pathogenic mechanisms of SARS-CoV-2 infection, the immediate and lasting effects of the cytokine storm on the central nervous system, and the consequences of neuroinflammation for the central nervous system. SARS-CoV-2 is a neuroinvasive virus capable of triggering a cytokine storm, with persistent effects in specific populations. Although our hypothesis is highly speculative, the impact of SARS-CoV-2 infection on the onset and progression of neurodegenerative and neuropsychiatric diseases of neuroinflammatory origin should be regarded as the potential cause of a delayed pandemic that may have a major public health impact in the medium to long term. Cognitive and neuropsychological function should be closely monitored in COVID-19 survivors.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.nrl.2020.04.002

Cites

15 of 15 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 23

  1. Kuiken, 2003, Newly discovered coronavirus as the primary cause of severe acute respiratory syndrome, Lancet, 362, 263, 10.1016/S0140-6736(03)13967-0 · DOI · Paper page
  2. Peiris, 2003, Coronavirus as a possible cause of severe acute respiratory syndrome, Lancet, 361, 1319, 10.1016/S0140-6736(03)13077-2 · DOI · Paper page
  3. Nicholls, 2003, SARS: clinical virology and pathogenesis, Respirology, 8, S6
  4. van den Brand, 2014, The pathology and pathogenesis of experimental severe acute respiratory syndrome and influenza in animal models, J Comp Pathol, 151, 83, 10.1016/j.jcpa.2014.01.004 · DOI · Paper page
  5. Channappanavar R., Fehr AR, Vijay R, Mack M, Zhao J, Meyerholz DK, et al. Dysregulated type I interferon and inflammatory monocyte-macrophage responses cause lethal pneumonia in SARS-CoV-infected mice. Cell Host Microbe 2016:19 (2): 181-193. · DOI · Paper page
  6. Davidson, 2015, Disease-promoting effects of type I interferons in viral, bacterial, and coinfections, J Interf Cytokine Res, 35, 252, 10.1089/jir.2014.0227 · DOI · Paper page
  7. Channappanavar, 2017, Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology, Semin Immunopathol., 39, 529, 10.1007/s00281-017-0629-x · DOI · Paper page
  8. Chien, 2006, Temporal changes in cytokine/chemokine profiles and pulmonary involvement in severe acute respiratory syndrome, Respirology, 11, 715, 10.1111/j.1440-1843.2006.00942.x · DOI · Paper page
  9. Hawkins, 2018, Chronic critical illness and the persistent inflammation, immunosuppression, and catabolism syndrome, Front Immunol., 9, 1511, 10.3389/fimmu.2018.01511 · DOI · Paper page
  10. Sheng, 1998, Distribution of inter-leukin-1-immunoreactive microglia in cerebral cortical lay-ers: implications for neuritic plaque formation in Alzheimer's disease, Neuropathol Appl Neurobiol, 24, 278, 10.1046/j.1365-2990.1998.00122.x · DOI · Paper page
  11. Vawter, 1996, TGFbeta1 and TGFbeta2 concentrations are elevated in Parkinson's disease in ventricular cerebrospinal fluid, Exp Neurol, 142, 313, 10.1006/exnr.1996.0200 · DOI · Paper page
  12. Barcia, 2005, Increased plasma levels of TNF-alpha but not of IL1-beta in MPTP-treated monkeys one year after the MPTP administration, Parkinsonism Relat Disord, 11, 435, 10.1016/j.parkreldis.2005.05.006 · DOI
  13. Magliozzi, 2018, Inflammatory intrathecal profiles and cortical damage in multiple sclerosis, Ann Neurol., 83, 739, 10.1002/ana.25197 · DOI · Paper page
  14. Reddy, 2013, Experimental models of status epilepticus and neuronal injury for evaluation of therapeutic interventions, Int J Mol Sci., 14, 18284, 10.3390/ijms140918284 · DOI · Paper page
  15. Lukassen, 2020, SARS-CoV-2 receptor ACE2 and TMPRSS2 are primarily expressed in bronchial transient secretory cells, EMBO J.
  16. Wong, 2020, Covid-19 and the Digestive System, J Gastroenterol Hepatol., 10.1111/jgh.15047 · DOI · Paper page
  17. Li, 2020, The neuroinvasive potential of SARS-CoV2 may be at least partially responsible for the respiratory failure of COVID-19 patients, T J Med Virol.
  18. Mao, 2020, Neurological manifestations of hospitalized patients with COVID-19 in Wuhan, China: a retrospective case series study, MedRXiv
  19. Xiang, 2020, First Case of 2019 novel coronavirus disease with encephalitis, ChinaXiv
  20. Jacomy, 2006, Human coronavirus OC43 infection induces chronic encephalitis leading to disabilities in BALB/C mice, Virology, 349, 335, 10.1016/j.virol.2006.01.049 · DOI · Paper page
  21. Miller, 2016, Keeping it in check: chronic viral infection and antiviral immunity in the brain, Nat Rev Neurosci., 17, 766, 10.1038/nrn.2016.140 · DOI
  22. Lin, 2018, Neuroinflammation, gut microbiome, and Alzheimer's Disease, Mol Neurobiol., 55, 8243, 10.1007/s12035-018-0983-2 · DOI · Paper page
  23. Matías-Guiu, 2020, ¿Es esperable que haya cuadros neurológicos por la pandemia de SARS2-CoV?, Neurologia, 10.1016/j.nrl.2020.03.001 · DOI

Cited by

See all 168

Metadata

Authors
Serrano-Castro, P. J., Estivill-Torrús, G., Cabezudo-García, P., Reyes-Bueno, J. A., Ciano Petersen, N., Aguilar-Castillo, M. J., Suárez-Pérez, J., Jiménez-Hernández, M. D., Moya-Molina, M. Á., Oliver-Martos, B., Arrabal-Gómez, C., & Rodríguez de Fonseca, F.
Venue
Neurología
Publisher
Elsevier BV
Published
2020-05
Volume
35
Issue
4
Pages
245-251
ISSN
0213-4853 (ISSN-L)
OpenAlex
W3020984757
Cited by
168
References
15
FWCI
13.63
Type
journal article
Language
es
Open access
gold
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.